SOHO 2018 | OPTIMISMM: benefits of a new triplet therapy for MM patients relapsing on lenalidomide

Meletios Dimopoulos

Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, gives an overview of the OPTIMISMM trial (NCT01734928) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX. This trial compared progression free survival (PFS) of dexamethasone/bortezomib and a triplet of dexamethasone, bortezomib and pomalidomide in patients with multiple myeloma (MM) that have previously been treated with lenalidomide. The positive PFS data from the triplet regimen, even in patients who have acquired resistance to lenalidomide, suggests a positivbe future for this therapy.

Share this video